AVALIAÇÃO DA ATIVIDADE IN VITRO DE CEFIDEROCOL, CEFTAZIDIMA/AVIBACTAM E MEROPENEM/VABORBACTAM CONTRA BACTÉRIAS MULTIRRESISTENTES OBTIDAS DE PACIENTES INTERNADOS EM HOSPITAL TERCIÁRIO NO SUL DO BRASIL

AVALIAÇÃO DA ATIVIDADE IN VITRO DE CEFIDEROCOL, CEFTAZIDIMA/AVIBACTAM E MEROPENEM/VABORBACTAM CONTRA BACTÉRIAS MULTIRRESISTENTES OBTIDAS DE PACIENTES INTERNADOS EM HOSPITAL TERCIÁRIO NO SUL DO BRASIL

Introdução: Novos antimicrobianos como ceftazidima-avibactam (CAZ/AVI), meropenem-varborbactam (MERO/VAR) e cefiderocol foram introduzidos na clínica médica nos últimos anos a fim de combater infecções causadas por contra bacilos gram-negativos (BGN) resistentes aos carbapenêmicos (RC). Destes, apen...

Full description

Bibliographic Details
Main Authors:	Patricia Orlandi Barth, Camila Mörschbächer Wilhelm, Aymê Duarte Echevarria, Kellen Figueira Tragnago, Richard Martins Carrassai, Afonso Luís Barth
Format:	Article
Language:	English
Published:	Elsevier 2023-10-01
Series:	Brazilian Journal of Infectious Diseases
Subjects:	cefiderocol ceftazidima-avibactam meropenem-vaborbactam bacilos gram-negativos resistência
Online Access:	http://www.sciencedirect.com/science/article/pii/S1413867023000831

Similar Items

Ceftazidima-Avibactam
by: Maria Natalia Ugalde Solera, et al.
Published: (2021-02-01)

SUSCETIBILIDADE DE ISOLADOS DE ENTEROBACTEREALES RESISTENTE AOS CARBAPENÊMICOS AOS ANTIBIÓTICOS CEFTAZIDIMA-AVIBACTAM, CEFTOLOZANE-TAZOBACTAM E CEFIDEROCOL
by: Deise Reis Carvalho, et al.
Published: (2023-10-01)

Meropenem/Vaborbactam and Cefiderocol as Combination or Monotherapy to Treat Multi-Drug Resistant Gram-Negative Infections: A Regional Cross-Sectional Survey from Piedmont Infectious Disease Unit Network (PIDUN)
by: Tommaso Lupia, et al.
Published: (2022-10-01)

Impacto da unitarização de ceftazidima + avibactam em um hospital público universitário durante a pandemia de COVID-19
by: Carlos Alberto Yasin Wayhs, et al.
Published: (2023-03-01)

Review of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem-Vaborbactam and Imipenem-Relebactam in Carbapenemase Producing Klebsiella pneumoniae Isolates
by: Özlem AYDEMİR, et al.
Published: (2023-09-01)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
by: Eric Wenzler, et al.
Published: (2020-10-01)

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms
by: Gabriele Bianco, et al.
Published: (2022-11-01)

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae
by: Petty LA, et al.
Published: (2018-09-01)

Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
by: François Barbier, et al.
Published: (2023-07-01)

In vitro activity of cefiderocol against comparators (ceftazidime-avibactam, ceftazidime-avibactam/ aztreonam combination, and colistin) against clinical isolates of meropenem-resistant Klebsiella pneumoniae from India
by: Kalyani Borde, et al.
Published: (2023-10-01)

Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing <i>K. pneumoniae</i> Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside
by: Alessandra Oliva, et al.
Published: (2021-06-01)

Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date
by: Herald F, et al.
Published: (2023-01-01)

Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion
by: Andrea Marino, et al.
Published: (2023-10-01)

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
by: Helio S. Sader, et al.
Published: (2021-12-01)

Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates
by: Dee Shortridge, et al.
Published: (2023-02-01)

Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections
by: Tanaya Bhowmick, et al.
Published: (2020-10-01)

Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study
by: Shrief R, et al.
Published: (2022-10-01)

In vitro-obtained meropenem-vaborbactam resistance mechanisms among clinical Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates
by: Jacqueline Findlay, et al.
Published: (2023-03-01)

Evaluation with E-test of the meropenem/vaborbactam association in carbapenem-resistant and sensitive negative control strains isolates of samples processed at the Laboratory of the Rivoli Hospital
by: Giuseppina Amarù, et al.
Published: (2022-05-01)

In Vitro Susceptibility of <i>Burkholderia pseudomallei</i> Isolates to Cefiderocol and Ceftazidime/Avibactam from Odisha, India
by: Jayanti Jena, et al.
Published: (2023-12-01)

Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections—In Vitro Susceptibility Testing
by: Małgorzata Brauncajs, et al.
Published: (2024-03-01)

Administración sistémica adjunta de moxifloxacina versus ciprofloxacina más metronidazol en el tratamiento de periodontitis crónica con presencia de bacilos entéricos Gram negativos: . Efectos clínicos y microbiológicos
by: Isabel Cristina Guzmán, et al.

Simultaneous post-neurosurgical ventriculitis and bacteraemia by two different strains of KPC-producing K. pneumoniae successfully treated with meropenem/vaborbactam and high dose of fosfomycin
by: Lorenzo Volpicelli, et al.
Published: (2024-06-01)

Treatment of UTIs Due to <i>Klebsiella pneumoniae</i> Carbapenemase-Producers: How to Use New Antibiotic Drugs? A Narrative Review
by: Caroline Chapelle, et al.
Published: (2021-11-01)

Prevalência de bacilos Gram-negativos não fermentadores de pacientes internados em Porto Alegre-RS
by: Bruno Deliberali, et al.
Published: (2011-10-01)

In vitro Activity of Meropenem-Vaborbactam versus Other Antibiotics Against Carbapenem-Resistant Escherichia coli from Southeastern China
by: Huang N, et al.
Published: (2021-06-01)

Electrochemical detection of cefiderocol for therapeutic drug monitoring
by: James McLeod, et al.
Published: (2021-12-01)

In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex.
by: Braulio Josué Méndez-Sotelo, et al.
Published: (2024-01-01)

Genotypic Evolution of Klebsiella pneumoniae Sequence Type 512 during Ceftazidime/Avibactam, Meropenem/Vaborbactam, and Cefiderocol Treatment, Italy
by: Gabriele Arcari, et al.
Published: (2023-11-01)

A Post-Neurosurgical Infection due to KPC-Producing Klebsiella pneumoniae Treated with Meropenem-Vaborbactam: A Case Report
by: Seohyun Choi, et al.
Published: (2022-09-01)

Treatment and diagnosis of severe KPC-producing Klebsiella pneumoniae infections: a perspective on what has changed over last decades
by: Daniele Roberto Giacobbe, et al.
Published: (2023-12-01)

Drug Regimens of Novel Antibiotics in Critically Ill Patients with Varying Renal Functions: A Rapid Review
by: Julie Gorham, et al.
Published: (2022-04-01)

Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
by: Stamatis Karakonstantis, et al.
Published: (2022-05-01)

Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant <i>Klebsiella pneumoniae</i>: A Retrospective Case Series and Literature Review
by: Alessandra Belati, et al.
Published: (2022-03-01)

Disc Diffusion and ComASP<sup>®</sup> Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine
by: Gabriele Bianco, et al.
Published: (2023-03-01)

Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography–Tandem Mass Spectrometry for Therapeutic Drug Monitoring
by: Rossella Barone, et al.
Published: (2023-04-01)

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
by: Richard G. Wunderink, et al.
Published: (2018-10-01)

ESPONDILODISCITE POR PSEUDOMONAS AERUGINOSA MULTIRRESISTENTE PÓS-COVID-19 TRATADO COM CEFTAZIDIMA-AVIBACTAM
by: Guilherme José da Nóbrega Danda
Published: (2022-01-01)

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance
by: Anna Duda-Madej, et al.
Published: (2023-11-01)

An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance Mechanisms
by: Sara Domingues, et al.
Published: (2023-06-01)